Iproniazid (brand/other names of Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, and irreversible monoamine oxidase inhibitor (MAOI). Monoamine oxidases is a family of FAD-containing enzymes and is an important target for antidepressant drugs. Iproniazid has been used as an antidepressive agent in many countries. It is a xenobiotic that was originally designed to treat tuberculosis, but was later found to act most prominently as an antidepressant drug. The medical use of iproniazid was discontinued in most of the world due to its hepatotoxicity, but remained in use in France until fairly recently.
Physicochemical Properties
| Molecular Formula | C9H13N3O | |
| Molecular Weight | 179.22 | |
| Exact Mass | 179.106 | |
| CAS # | 54-92-2 | |
| Related CAS # | Iproniazid phosphate;305-33-9 | |
| PubChem CID | 3748 | |
| Appearance | White to off-white solid powder | |
| Melting Point | 161-161.5 | |
| LogP | 1.506 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 3 | |
| Rotatable Bond Count | 3 | |
| Heavy Atom Count | 13 | |
| Complexity | 164 | |
| Defined Atom Stereocenter Count | 0 | |
| InChi Key | NYMGNSNKLVNMIA-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13) | |
| Chemical Name | N'-propan-2-ylpyridine-4-carbohydrazide | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References | Molecules.2014 Nov 14;19(11):18620-31;https://en.wikipedia.org/wiki/Iproniazid | ||
| Additional Infomation |
Iproniazid is a carbohydrazide and a member of pyridines. Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine. An irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity. Drug Indication For the treatment of depression (originally intended to treat tuberculosis). Pharmacodynamics Iproniazid is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (13.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5797 mL | 27.8987 mL | 55.7973 mL | |
| 5 mM | 1.1159 mL | 5.5797 mL | 11.1595 mL | |
| 10 mM | 0.5580 mL | 2.7899 mL | 5.5797 mL |